• Lonza increases capacity and capabilities in Visp (CH) with the completion of a new line for cGMP clinical and commercial drug product manufacturing
   
• The line is fully operational, and the first customer batches will be filled in April 2023
   
• This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering

Basel, Switzerland, 29 March 2023 – Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, today announced the completion of its planned cGMP clinical and commercial drug product manufacturing line in Visp (CH).

The new line will support customers with a range of drug product manufacturing needs for both clinical and commercial supply. Set in a 1,200 sqm cGMP facility, it includes a state-of-the-art liquid and lyophilized vial filling isolator line for multiple modalities that fulfils the GMP Annex 1 requirement for the manufacture of sterile products¹. The line is already fully operational and cGMP licensed, with the first customer batches due to be filled in April 2023.

The asset is part of Lonza’s Ibex^® Biopark and complements recent expansions at the Visp site, including in bioconjugation, mammalian manufacturing and microbial development. Together, these developments support Lonza’s long-term growth strategy to build capacity in areas of high customer demand, and its ambition to provide flexible end-to-end solutions for customers at a single location – from drug substance to drug product.

The completion of the line in Visp also marks a significant milestone in the growth of Lonza’s leading DPS offering. It follows the recent groundbreaking of a new facility in Stein (CH), which will be dedicated to large-scale commercial drug product manufacturing and is being delivered through an investment of approximately CHF 500 million. Ongoing investment to expand the DPS network is enabling Lonza to offer end-to-end solutions across the whole product lifecycle, including clinical and commercial supply.

Peter Droc, Head of Drug Product Services, Lonza, commented: “Since establishing Drug Product Services in 2016, we have built a leading offering that meets customer needs across the pharma and biotech value chain, from formulation to filling. With demand for drug product manufacturing continuing to increase, this new cGMP clinical and commercial line in Visp launches at a crucial time for our customers and market. It also strengthens our DPS capabilities, by enabling us to offer customers a flexible and integrated service offering from a single location.”

The new manufacturing line in Visp will be supported by Lonza’s Drug Product Center of Excellence in Stücki Technology Park, Basel (CH). The Stücki facility offers a range of drug product development services to customers, including formulation and process development, analytical development and quality control.

Additional Information
For more information about Lonza’s Drug Product Services offering, visit: https://www.lonza.com/biologics/parenteral-drug-product

About Lonza
Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene and Capsules & Health Ingredients. Our unparalleled breadth of offerings across divisions enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 17,500 full-time employees, we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 6.2 billion with a CORE EBITDA of CHF 2.0 billion in Full-Year 2022. Find out more at www.lonza.com

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com

Lyle Wheeler
Investor Relations
Lonza Group Ltd
Tel +41 79 154 9522
lyle.wheeler@lonza.com

Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Privacy Policy link

To immediately delete all the data